Worldwide industrial services company Harsco Corp. last week said its SGB access services division has been awarded two contracts totaling more than $1.6 million to support construction of a new GlaxoSmithKline Vaccine Plant in Singapore.
The new contracts underscore the accelerating growth of SGBâ€™s branch operations in Singapore as one of the countryâ€™s Ieading access services and rental equipment suppliers and a major player in some of Singaporeâ€™s most prestigious construction projects. The new plant is GSKâ€™s biggest vaccine investment in Asia and will be the first such facility in Singapore, fast becoming a major world center for biotechnology and pharmaceutical production.
Growth in the Asia-Pacific sector is one of the cornerstones of Harscoâ€™s strategic objectives for increasing stockholder value through an expanded presence in the worldâ€™s developing economies, including Eastern Europe, Latin America, the Middle East and Africa. Harscoâ€™s international footprint in 45 countries accounted for more than 60 percent of the companyâ€™s 2006 revenues and nearly 70 percent in the most recent quarter.
The SGB division is part of Harrisburg, Pa.-based Harscoâ€™s global Access Services business group. The companyâ€™s North America-based Patent division is No. 18 on the RER 100.